Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

JMP Securities maintained a positive stance on Exelixis (NASDAQ:EXEL) stock, reiterating a Market Outperform rating with a ...

Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $40.00 target ...

A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

Truist raised the firm’s price target on Exelixis (EXEL) to $43 from $42 and keeps a Buy rating on the shares. With more mature overall ...

Exelixis Inc. has synthesized fused pyrazole derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Stephens reiterated their equal weight rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report ...

Oppenheimer shifts to a neutral stance on Exelixis, questioning differentiation between zanzalintinib and cabozantinib ...